Therapeutic Potential for Cannabis and Cannabinoids

• Other Authors: Raup-Konsavage, Wesley M. (Editor)
• Format: Electronic Book Chapter
• Language: English
• Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
• Subjects: Medicine; anti-microbial activity; anti-biofilm activity; Cannabis sativa L.; endocannabinoids; gut microbiota; pathogens; phytocannabinoids; synovial fibroblast; rheumatoid arthritis; cannabis; tetrahydrocannabinol; cytokines; calcium; PBMC; cannabinoid receptors; TRPA1; 2-hydroxy oleic acid; anandamide; anti Bcl2; endocannabinoid system; membrane lipid therapy; neuroblastoma; N-arachidonoylethanolamine; cortisol; chronic pain; injury; autism spectrum disorder; cannabinoids; cannabidiol; clinical trials; randomized controlled; sleep; child psychiatry; developmental disorders; rat; post-traumatic stress disorder (PTSD); URB597; mGluR5; CB1 receptor; fatty acid amide hydrolase (FAAH); β-catenin; cannabinoid; immune; macrophage; elderly; inflammatory bowel disease; D9 tetrahydrocannabinol; nitric oxide; epilepsy; animal model; cognitive dysfunction; zebrafish; ∆9-tetrahydrocannabinol; THC; CBD; prefrontal cortex; striatum; BDNF; aging; age-related diseases; neuropathic pain; anxiety; inhalation; HRQoL; phytochemistry; terpenes; synergy; entourage effect; biosynthesis; HIV; cannabidiol (CBD); tetrahydrocannabinol (THC); chronic liver diseases; quality of life; pilot clinical trial; MMP-2; MMP-9; VSMC; H9c2 cells; glucose; cell proliferation; apoptosis; cardiovascular disease; FAAH inhibitors; MGL inhibitors; neonatal brain injury; hypoxia-ischemia; neuroprotection; neurogenesis; inflammation; bile acids; transcriptomics; estrogen deficiency; ovariectomized mice; postmenopause; gut organoids; ghrelin; GHSR signaling; late adolescence; medical cannabis; polypharmacy; n/a
• Online Access: DOAB: download the publication; DOAB: description of the publication

Cannabis has a history of medical use dating back millennia; however, the use of cannabis for medicinal purposes fell out of favor in the middle of the last century. There is currently a renewed interest in the potential medicinal value of this plant, as well as individual compounds produced by Cannabis (as well as synthetic analogs). Currently, nearly 50 countries permit the medical use of cannabis, and over a dozen other countries have legalized cannabis-based products (CBD, Sativex, Dronabinol, etc.) for medical use. While there exists a plethora of anecdotal reports indicating that cannabis can treat a variety of diseases, there is a limited amount of strong, evidence-based scientific data to support these claims. This Special Edition of Biomedicines, "Therapeutic Potential for Cannabis and Cannabinoids", was dedicated to providing evidence for the medicinal value of cannabis to treat human illness and disease. Topics included, but were not limited to, preclinical animal models examining the efficacy of cannabis and cannabinoid derivatives on pain, anxiety, cancer, and other diseases; and cell and molecular models of cannabinoid pharmacokinetics, drug-drug interactions, and disease treatment. These studies are of great importance not only for progressing the cannabis field, but also for validating the use of cannabis and cannabinoids as therapeutics.